Login / Signup

A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.

Jiyun LeeSehhoon ParkHyun Ae JungSe-Hoon LeeSeyoung SeoSung-Bae KimJi-Won KimKeun-Wook LeeEun Joo KangJu Won KimYoon Ji ChoiByoung-Yong ShimHo-Jung AnLee Chun ParkSeong Hoon ShinJae-Joon KimSo Yeon OhMin Kyoung KimMyung-Ju Ahn
Published in: Cancer (2023)
Salivary duct carcinoma (SDC) is uncommon but is the most aggressive subtype of salivary gland carcinomas. SDC shares morphological and histological similarities with invasive ductal carcinoma of breast, which led to an investigation of hormonal receptor and human epidermal growth factor receptor 2 (HER2)/neu expression status in SDC. In this study, patients with HER2-positive SDC were enrolled and treated with combination of docetaxel-polymeric micelle and trastuzumab-pkrb. Promising antitumor activities were shown with objective response rate of 69.8%, disease control rate of 93.0%, median progression-free survival of 7.9 months, median duration of response of 6.7 months, and median overall survival of 23.3 months.
Keyphrases